Zura Bio Ltd. Files 8-K: Board Changes and Financials
Ticker: ZURA · Form: 8-K · Filed: Sep 30, 2025 · CIK: 1855644
| Field | Detail |
|---|---|
| Company | Zura Bio Ltd (ZURA) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, financials
TL;DR
Zura Bio filed an 8-K detailing board changes and executive comp. Check for new leadership direction.
AI Summary
Zura Bio Ltd. announced on September 24, 2025, a change in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, with the company's principal executive offices located in La Jolla, CA.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can affect stock price, and changes in leadership or financial disclosures warrant careful review.
Key Players & Entities
- Zura Bio Ltd (company) — Registrant
- 001-40598 (company) — SEC File Number
- La Jolla, CA (location) — Business Address
- September 24, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' under Item 5.02, but the specific names and details of the changes are not provided in the excerpt.
What are the details of the compensatory arrangements for certain officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' under Item 5.02, but the specific details of these arrangements are not included in the provided text.
What is the primary business of Zura Bio Ltd?
Zura Bio Ltd. is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' industry, as indicated by its Standard Industrial Classification code [2836].
When was Zura Bio Ltd. incorporated or organized?
Zura Bio Ltd. is incorporated in the Cayman Islands, as stated in the filing.
What is the fiscal year end for Zura Bio Ltd?
The fiscal year end for Zura Bio Ltd. is December 31 (1231).
Filing Stats: 999 words · 4 min read · ~3 pages · Grade level 17.4 · Accepted 2025-09-30 16:10:30
Key Financial Figures
- $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar
Filing Documents
- tm2527486d1_8k.htm (8-K) — 31KB
- tm2527486d1_ex10-1.htm (EX-10.1) — 98KB
- 0001104659-25-095024.txt ( ) — 316KB
- zura-20250924.xsd (EX-101.SCH) — 3KB
- zura-20250924_lab.xml (EX-101.LAB) — 33KB
- zura-20250924_pre.xml (EX-101.PRE) — 22KB
- tm2527486d1_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 24, 2025, the Board of Directors of (the "Board") of Zura Bio Limited (the "Company") adopted an Executive Severance Benefit Plan (the "Severance Plan") pursuant to which certain employees, including the Company's current named executive officers, are eligible to participate. Pursuant to the Severance Plan, if an Eligible Employee's (as defined in the Severance Plan) employment terminates (a) without Cause (as defined in the Severance Plan) and other than as a result of death or Disability (as defined in the Severance Plan) or (b) due to resignation for Good Reason (as defined in the Severance Plan), in either case, at least 91 days following the commencement of such Eligible Employee's employment with the Company, then, subject to execution of a separation agreement containing a customary general waiver and release of all claims in favor of the Company and its Affiliates (as defined in the Severance Plan) and certain other conditions set forth in the Severance Plan, such Eligible Employee is entitled to a lump sum payment equal to (x) 12 months of such Eligible Employee's base salary, in the case of the Company's Chief Executive Officer (the "Chief Executive Officer"), or (y) nine months of such Eligible Employee's base salary, in the case of the Company's other named executive officers and certain other executives. If an Eligible Employee's employment terminates within the time period beginning on the date of the closing of a Change in Control (as defined in the Severance Plan) and ending 12 months following the closing of the Change in Control (a) without Cause and other than as a result of death or Disability or (b) due to resignation for Good Reason, in either case, at least 91 days following the commencement of such Eligible Employee's employment with the Company, then, subject to execution o
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 10.1 Zura Bio Limited Executive Severance Benefit Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZURA BIO LIMITED Date: September 30, 2025 By: /s/ Kim Davis Kim Davis Chief Operating Officer, Chief Legal Officer and Corporate Secretary